• bsi-innovation
  • bsi-learning
  • bsi-people
  • bsi-wealth

A device for metastatic cancers

Viatar is at the bleeding edge of innovation – It’s a cancer dialysis med-tech  focused on the treatment of patients making metastatic cancers a chronic rather than fatal condition.

Click here for an animated video of how it works – http://www.mediafire.com/download/xb4avvy8i4vd4di/VTO_A2.mov
Viatar is looking to be listed in the ASX listed on 26 July 2016 raising $13.6m.
We are hosting a lunch with Viatar’s leader Ilan Reich on Friday 1 July. With Viatar’s founder, Ilan Reich 
( see http://www.viatarctcsolutions.com/ir-management.html) 

Viatar’s value proposition is

 – proven technology for removal of over 90% of a cancer patient’s lethal circulating tumor cells

   – few competitors and a more effective and affordable devices

– pivotal US trial results imminent, major regulatory approvals in US and commercialization in Europe 2016

   – a sophisticated and supportive investor based of over 100, and in excess of USD 21M in funding to date

   – a large growing market with regulated growth drivers and existing reimbursement regime in the US

– An ASX listing broadens Viatar’s stakeholder base to support global play with uplift to NASDAQ potential, Q4 ‘16. 


( Contact me if interested and I will refer you to the powers that be) 

Posted on June 25, 2016

Leave a Reply

Your email address will not be published. Required fields are marked *


Contact us today to find out how we can make your business grow!
Ph: 02 9126 9100  Email: info@bsi.com.au
Level 9, Angel Place,123 Pitt Street
Sydney NSW 2000

© Copyright 2024 BSI